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Abstract 
The human embryonic stem cell line RCe018-A (RC-14) was derived under quality assured 
compliance with UK regulation, European Union Directives and International guidance for tissue 
procurement, processing and storage according to Good Manufacturing Practice (GMP) standards.  
The cell line was derived from a blastocyst stage embryo voluntarily donated as unsuitable or surplus 
to fertility requirements following informed consent.   RCe018-A (RC-14) shows normal pluripotency 
marker expression and differentiation to the three germ layers in vitro.  It has a male karyotype with 
an extra copy of chromosome 8 (47XY, +8).  Microsatellite PCR identity, HLA and blood group typing 
data is available.   
Resource table 
 
Name of stem cell 
construct     
RCe018-A 
  
Alternative name RC-14, RC14 
  
Institution   Roslin Cells Ltd. 
  
Person who created 
resource   
B.J. Tye, K. Bruce, P. Dand, G. Russell, D.M.  Collins, A. Greenshields, K. 
McDonald, H. Bradburn, A. Laurie 
  
Contact person and 
email   
Paul.desousa@roslincells.com; Paul.desousa@ed.ac.uk 
Janet.downie@roslincells.com 
Aidan.courtney@roslincells.com 
Malcolm.bateman@roslinfoundation.com 
  
Date archived/stock 
date   
16 May 2011 (seed bank) 
  
Type of resource   Biological reagent: cell line 
  
Sub-type   hESC, clinical grade 
  
Origin  Blastocyst with ICM and Trophoblast 
  
Key transcription 
factors   
Oct4 (confirmed by flow cytometry), 
  
Authentication   See Quality Control Certificate of Analysis (Fig. 1) 
  
Link to related 
literature (direct URL 
links and full 
references)   
N/A 
  
Information in public 
databases   
http://hpscreg.eu/cell-line/RCe018-A 
  
Ethics   Informed consent obtained.  Scotland A Research Ethics committee approval 
obtained (07/MRE00/56).  Conducted under the UK Human Fertilisation and 
Embryology Authority licence no R0136 to centre 0202 and UK Human Tissue 
Authority (HTA) licensing number 22631.   
 
Resource details 
RCe018-A (RC-14) was derived from a blastocyst stage embryo that was surplus to requirement or 
unsuitable for clinical use.   Human embryonic stem cell (hESC) isolation, expansion and qualification 
was performed in a facilities whose specification, operation and monitoring complied with GMP 
standards enabling; i) a fully traceable procurement procedure with informed ethical consent which 
includes provision for commercial use, ii) detailed medical history and blood borne virus (BBV) 
screening of donors, and iii) compilation of a cell line history providing details on hESC 
manufacturing process and quality control testing regime.  
Human ESC culture and processing was performed in a grade A tissue culture cabinet in a grade B 
clean room environment monitored for particulate and microbiological contamination during cell 
processing in accordance with Rules and Guidance for Pharmaceutical Manufacturers and 
Distributors - The Orange Guide, compiled by the UK Medicines Healthcare Products Regulatory 
Authority (Go to: https://www.gov.uk/guidance/good-manufacturing-practice-and-good-
distribution-practice). Accordingly, the facility was operating under a mature Quality Management 
System, compliant with ISO9001:2008 standards. HESC derivation was performed under licensure 
from the UK HFEA (R0136 to centre 0202) and HTA (Licensing Number 22631).   
HESC derivation involved whole embryo outgrowth on mitotically inactivated human dermal 
fibroblast (HDF) feeder cells. HDFs were derived and manufactured according to GMP and had been 
approved for clinical use by the Food and Drug Administration, USA.  During derivation on HDFs, 
hESCs were grown in a xeno-free cell therapy grade media (XF KODMEM) supplemented with xeno-
free human recombinant bFGF. HESCs were subsequently expanded in a GMP grade serum-free 
medium (StemPro hESC Serum Free Medium) on a xeno-free matrix (CellStart). The former 
contained bovine serum albumin (BSA) from a Transmissible Spongioform Encephalopathy (TSE)-free 
country of origin.  The cell line was cryopreserved in a GMP compliant cryopreservation solution 
(CryoStor CS10). 
By flow cytometry, RCe018-A (RC-14) expressed the pluripotency makers Oct-4, Tra-1-60 and SSEA-4 
(87.7%, 55.4% and 94.8%, respectively), whereas low expression of the differentiation marker SSEA-
1 (1.0%) was observed (Fig. 1, Fig. 2).  Differentiation to the three germ layers, endoderm, ectoderm 
and mesoderm, was demonstrated using embryoid body formation in vitro, and expression of the 
germ layer markers α-fetoprotein, β-tubulin and muscle actin was observed (Fig. 3).  
A microsatellite PCR profile has been obtained for the cell line, and HLA Class I and II typing is 
available (Table 1).  Blood group genotyping gave the blood group O1O1 (Table 1).   
Verification and authentication  
The cell line was analysed for genome stability by G-banding and showed a male genotype with 
trisomy 8 (47XY, +8) in all cells analysed (Fig. 4).  The cell line is free from mycoplasma contamination 
as determined by RT-qPCR.   
Materials and methods 
Ethics  
Derivation of hESC from surplus to requirement and failed to fertilise/develop embryos was 
approved by The Scotland A Research Ethics Committee and local ethics board at participating 
fertility clinics and conducted under licence no R0136 from the UK HFEA with informed donor 
consent.  The processing and storage of hESC cells for human application was conducted under 
licence number 22631 from the UK Human Tissue Authority.  
Cell culture 
Fresh embryos were cultured in Sydney blastocyst medium (Cook Medical, Hertfordshire, UK) after 
day 3 of development.  Embryos were cultured at 36.5 - 37.5°C, 5.0 ± 0.5% CO2, 5.0 ± 0.5% O2 in 
drops under paraffin oil (Cook Medical) and transferred to fresh medium at least every 2-3 days.   
By Day 8 of development, embryos were placed in derivation conditions consisting of mitotically 
inactivated GMP grade neonatal human dermal fibroblasts (HDFs) (Forticell Biosciences, NJ, USA) on 
tissue culture plastic in XF KODMEM medium (Knockout-DMEM, 15% KOSR-XF, 2 mM L-glutamine, 
1% MEM Non essential amino acids, 2% XF Growth Factor Cocktail, 0.1 mM β-mercaptoethanol 
(ThermoFisher Scientific, Paisley, UK) supplemented with 80 ng/ml human bFGF (ThermoFisher 
Scientific).      When available, cell therapy system quality reagents were used.  Assisted hatching was 
performed by removing the zona pellucidae mechanically using Swemed cutting tools (Vitrolife, 
Göteborg, Sweden).   
HDF cells were cultured in DMEM (Lonza, Slough, UK), 10% Pharma grade FCS (GE Healthcare (PAA), 
Buckinghamshire, UK) and 2 mM L-glutamine (ThermoFisher Scientific).  HDF were mitotically 
inactivated using gamma irradiation at 50 Gy using a Gammacell Elite 1000 machine.  For use as a 
feeder layer, irradiated HDFs were plated at 50000 cells/cm2 in XF KODMEM medium supplemented 
with 80ng/ml human bFGF (ThermoFisher Scientific).  Cells were cultured at 36.5 - 37.5°C, 5.0 ± 0.5% 
CO2, 5.0 ± 0.5% O2 and 50% medium exchanged 6 days a week.   
The established cell line was expanded and banked using CellStart matrix and Stempro hESC Serum 
Free Medium (cell therapy system quality reagents, ThermoFisher Scientific).  This contained BSA 
from a TSE-free country of origin. Passaging was performed mechanically using an EZ passage tool 
(ThermoFisher Scientific).  hESC lines were expanded to 25-30 wells of a 6-well plate and 
cryopreserved in 0.5-1 ml Cryostor CS10 (Biolife Solution, Washington, USA) using an EF600-107  
controlled rate freezer (Grant Instruments, Cambridge, UK) before being stored in a -150°C freezer 
(Panasonic Biomedical, Loughborough, UK).   
Mycoplasma 
In process mycoplasma detection was performed using Applied Biosystems PrepSEQ™ Mycoplasma 
Nucleic Acid Extraction Kit and MicroSEQ™ Mycoplasma Real-Time PCR Detection Kit (ThermoFisher 
Scientific (Applied Biosystems)) according to the manufacturer’s instruction.  
Endotoxin 
Endotoxin levels were determined using the Kinetic-QCL assay (Lonza) and an incubating plate 
reader (BioTek ELx808) according to the manufacturer’s instructions. Briefly, an unknown sample 
was compared with a standard curve of known levels of control endotoxin.  An assay was deemed 
valid if the coefficient of correlation, r ≥ 0.980 and the CV (%) for the standard curve was ≤10%, and 
the reaction time of the negative control was greater than the reaction time of the lowest standard 
on the standard curve.   
Flow cytometry  
Pluripotency was determined using the Human and Mouse Pluripotent Stem Cell Analysis kit (BD, 
Oxford, UK).   Oct 3/4 and SSEA-4 were included as pluripotency markers, and SSEA-1 as a 
differentiation marker.   FITC conjugated Tra-1-60 (BD) was used as an additional pluripotency 
marker.  Fixed and permeabilised cells were analysed using a FACS Aria flow cytometer (BD) or a 
Guava easyCyte flow cytometer (Millipore, Watford, UK).  Percentage expression of each marker was 
compared to isotype control or unstained cells.   
Viability 
Viability was determined using the Guava ViaCount assay.  Briefly, the Guava Viacount reagent 
(Millipore) containing a nuclear and a viability dye, was mixed with a single cell suspension, 
incubated for 5 minutes and analysed using the Guava easyCyte flow cytometer (Millipore).  Total 
cell count, viable cell count and percentage viable cells was obtained.   
 
In vitro differentiation 
hESCs were pre-treated for 1 h with 10 µM ROCK inhibitor in Stempro hESC SFM (ThermoFisher 
Scientific) and embryoid bodies (EBs) generated in ultra low attachment plates (Corning) for 7 days 
before being transferred into EB medium (20% FBS (GE Healthcare (PAA)), 80% KO-DMEM 1 mM L-
glutamine, 3.5 µM -mercaptoethanol, 1 % nonessential amino acids (all ThermoFisher Scientific)), 
on glass slide tissue culture chambers (Nunc, ThermoFisher Scientific) coated with 0.2% gelatin 
(Sigma Aldrich, Dorset, UK) at 0.1 ml/cm2 for 14 days. 
Immunocytochemistry 
Cells were fixed in 4% paraformaldehyde (ThermoFisher Scientific (Alfa Aesar)), permeabilised using 
100% ethanol (ThermoFisher Scientific) and stained with AFP (1:500; Sigma), β-tubulin III (1:1000; 
Sigma) and muscle-specific actin (1:50; DAKO, Glostrup, Denmark) and secondary antibody anti 
mouse IgG-AlexaFluor 488 (1:200; Sigma).  Images were acquired using a Zeiss S100 Axiovert 
fluorescence microscope or Nikon eC1 confocal microscope 
Genomic analysis and outsourced assays 
All outsourced assays were carried out under a Quality and Technical Agreement.   DNA was 
extracted using the QIAamp DNA Mini kit (Qiagen, Manchester, UK) according to manufacturer’s 
recommendations and provided in recommended quantities to the service providers.     
Microsatellite PCR, or Short Tandem Repeat analysis, was used to determine cell line identity and 
was carried out by Public Health England.   A profile was obtained for the following core alleles: 
vWA, D16S539, Amelogenin, THO1, CSF1PO, D5S818, D75820, D135317 and TPOX.   
Human Leukocyte Antigen (HLA) tissue typing was carried out by the Scottish National Blood 
Transfusion Service. 
Blood group genotyping was carried out by the Molecular Diagnostics laboratory at NHSBT. 
Karyotype analysis was carried out by the Western General Cytogenetics Laboratory (Edinburgh, UK).  
Live cells at 60-70% confluency were shipped in warm containers, fixed and analysed by standard G-
banding analysis.  For clinical grade lines, 30 spreads were analysed.    
Viral screening for cytomegalovirus (CMV), Human T-cell lymphotropic virus (HTLV)-1, Human 
immunodeficiency virus (HIV)-1, Hepatitis C virus (HCV), Hepatitis B virus (HBV) and Epstein-Barr 
virus (EBV) was carried out by The Doctors Laboratory (London, UK).   
Figures and tables  
 
 Fig. 1.  Quality Control Certificate of Analysis for RCe018-A (RC-14) P28A seed lot.   
 
 Fig. 2.  RCe018-A (RC-14) was subjected to flow cytometry analysis for markers of pluripotency with 
specific antibody (top row) or isotype control (bottom row) as indicated above the histograms. 
Percentage staining is indicated in the Certificate of Analysis (Fig.1).   
 
Fig. 3.  In vitro differentiation of RCe018-A (RC-14) to ectoderm (β-tubulin III), mesoderm (muscle 
Actin), and endoderm (α-fetoprotein).  Specific staining shown in green, cell nuclei are 
counterstained with DAPI (blue).    
Fig. 4.  RCe018-A (RC-14) was analysed by Giesma staining of 30 metaphase spreads and showed a 
47XY, +8 male karyotype in all spreads analysed.   
Table 1.  Microsatellite PCR, blood group and HLA tissue typing results for RCe018-A (RC-14).   
Microsatellite PCR results 
D3S1358 1 D3S1358 2 vWA 1 vWA 2 D16S539 1 D16S539 2 D2S1338 1 D2S1338 2 
16 16 16 16 10 12 17 24 
        Amelogenin 1 Amelogenin 2 D8S1179 1 D8S1179 2 D21S11 1 D21S11 2 D18S51 1 D18S51 2 
X Y 12 12 30 31.2 16 16 
        D19S433 1 D19S433 2 THO1 1 THO1 2 FGA 1 FGA 2 CSF1PO 1 CSF1PO 2 
13 16 9.3 9.3 20 24 10 10 
        D5S818 1 D5S818 2 D7S820 1 D7S820 2 D13S317 1 D13S317 2 TPOX 1 TPOX 2 
9 11 8.2 12 11 14 8 12 
* Peak falls below threshold to confidently score. 
        
Blood group genotyping 
RhD RhC Rhc RhE Rhe Fy a Fy b Fy GATA 
pos pos neg neg pos pos neg neg 
        Jka Jkb K k  M N S  s  
pos neg neg pos pos pos neg pos 
        Do a Do b ABO   
   neg pos O1O1   
   
        
HLA tissue typing 
HLA Class I Type HLA-A*01, A*02; B*07, B*08; C*07 
HLA Class II Type HLA-DRB1*03; DRB3*01/02; DQB1*02 
Comment DRB1*03 is expressed serologically as DR17. 
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